ZA947444B - Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide - Google Patents
Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamideInfo
- Publication number
- ZA947444B ZA947444B ZA947444A ZA947444A ZA947444B ZA 947444 B ZA947444 B ZA 947444B ZA 947444 A ZA947444 A ZA 947444A ZA 947444 A ZA947444 A ZA 947444A ZA 947444 B ZA947444 B ZA 947444B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrolidineacetamide
- anxiety
- oxo
- alpha
- ethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Anesthesiology (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939319732A GB9319732D0 (en) | 1993-09-24 | 1993-09-24 | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA947444B true ZA947444B (en) | 1995-05-11 |
Family
ID=10742476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA947444A ZA947444B (en) | 1993-09-24 | 1994-09-23 | Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5447952A (xx) |
| EP (1) | EP0645139B1 (xx) |
| JP (1) | JP3688735B2 (xx) |
| KR (1) | KR950007848A (xx) |
| AT (1) | ATE191849T1 (xx) |
| AU (1) | AU672334B2 (xx) |
| CA (1) | CA2132509A1 (xx) |
| DE (1) | DE69424009T2 (xx) |
| ES (1) | ES2145818T3 (xx) |
| GB (1) | GB9319732D0 (xx) |
| HU (1) | HU217124B (xx) |
| NO (1) | NO943521L (xx) |
| NZ (1) | NZ264506A (xx) |
| RU (1) | RU2142274C1 (xx) |
| SG (1) | SG86284A1 (xx) |
| TW (1) | TW283642B (xx) |
| ZA (1) | ZA947444B (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525347A (en) * | 1995-01-31 | 1996-06-11 | Medical University Of South Carolina | Composition and methods for treating performance anxiety |
| TWI238062B (en) | 1999-12-01 | 2005-08-21 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| WO2007086891A1 (en) * | 2006-01-24 | 2007-08-02 | Teva Pharmaceutical Industries Ltd. | Levetiracetam formulations and methods for their manufacture |
| KR101065239B1 (ko) * | 2006-03-15 | 2011-09-16 | 액테리온 파마슈티칼 리미티드 | 기억 기능을 증진하는 테트라히드로이소퀴놀린 유도체 |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| CN101730696B (zh) * | 2007-07-03 | 2013-01-09 | 埃科特莱茵药品有限公司 | 3-氮杂-二环[3.3.0]辛烷化合物 |
| BRPI0814593A2 (pt) * | 2007-07-27 | 2015-01-20 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica que o contém e uso do composto. |
| BRPI0920342A2 (pt) | 2008-10-16 | 2020-06-23 | The Johns Hopkins University | Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo |
| US8191547B2 (en) * | 2008-10-23 | 2012-06-05 | S-2Tech Llc | Portable solar-heating system having an inflatable solar collector |
| US20100159009A1 (en) * | 2008-12-24 | 2010-06-24 | Zhongshui Yu | Controlled-release formulations |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| CA2789014C (en) * | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| CA2826765C (en) * | 2011-02-09 | 2021-04-06 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
| SG11202105863PA (en) * | 2018-12-04 | 2021-07-29 | Metys Pharmaceuticals AG | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB8827389D0 (en) | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
-
1993
- 1993-09-24 GB GB939319732A patent/GB9319732D0/en active Pending
-
1994
- 1994-09-20 CA CA002132509A patent/CA2132509A1/en not_active Abandoned
- 1994-09-20 US US08/309,186 patent/US5447952A/en not_active Expired - Lifetime
- 1994-09-20 HU HU9402704A patent/HU217124B/hu not_active IP Right Cessation
- 1994-09-21 AT AT94870152T patent/ATE191849T1/de not_active IP Right Cessation
- 1994-09-21 SG SG9502212A patent/SG86284A1/en unknown
- 1994-09-21 ES ES94870152T patent/ES2145818T3/es not_active Expired - Lifetime
- 1994-09-21 NZ NZ264506A patent/NZ264506A/en unknown
- 1994-09-21 DE DE69424009T patent/DE69424009T2/de not_active Expired - Lifetime
- 1994-09-21 EP EP94870152A patent/EP0645139B1/fr not_active Expired - Lifetime
- 1994-09-21 TW TW083108691A patent/TW283642B/zh active
- 1994-09-22 NO NO943521A patent/NO943521L/no unknown
- 1994-09-22 JP JP22833194A patent/JP3688735B2/ja not_active Expired - Fee Related
- 1994-09-22 AU AU74169/94A patent/AU672334B2/en not_active Ceased
- 1994-09-23 RU RU94034109A patent/RU2142274C1/ru active
- 1994-09-23 ZA ZA947444A patent/ZA947444B/xx unknown
- 1994-09-23 KR KR1019940024170A patent/KR950007848A/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| SG86284A1 (en) | 2002-02-19 |
| KR950007848A (ko) | 1995-04-15 |
| JPH07149639A (ja) | 1995-06-13 |
| AU7416994A (en) | 1995-04-06 |
| DE69424009D1 (de) | 2000-05-25 |
| AU672334B2 (en) | 1996-09-26 |
| GB9319732D0 (en) | 1993-11-10 |
| NO943521D0 (no) | 1994-09-22 |
| CA2132509A1 (en) | 1995-03-25 |
| RU2142274C1 (ru) | 1999-12-10 |
| HUT68299A (en) | 1995-06-28 |
| TW283642B (xx) | 1996-08-21 |
| ATE191849T1 (de) | 2000-05-15 |
| US5447952A (en) | 1995-09-05 |
| NO943521L (no) | 1995-03-27 |
| JP3688735B2 (ja) | 2005-08-31 |
| NZ264506A (en) | 1997-09-22 |
| DE69424009T2 (de) | 2000-09-14 |
| EP0645139A1 (fr) | 1995-03-29 |
| HU217124B (hu) | 1999-11-29 |
| ES2145818T3 (es) | 2000-07-16 |
| EP0645139B1 (fr) | 2000-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW283642B (xx) | ||
| TW249226B (xx) | ||
| EP0562049A4 (en) | Novel 4-arylpiperazines and 4-arylpiperidines | |
| ZA925128B (en) | Pyrrolidine derivatives,their preparation and medicaments containing them | |
| DK0559413T3 (xx) | ||
| AU3354895A (en) | Novel medicinal use of 5ht3 antagonist | |
| GR3005470T3 (xx) | ||
| GR3019760T3 (en) | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | |
| GR1002598B (el) | Παραγωγα επι-επιβατιδινης. | |
| AU639322B2 (en) | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds | |
| EP0469782A3 (en) | Treatment of cataract with prostacyclin compounds | |
| NO920984D0 (no) | Fremgangsmaate for diastereoselektiv reduktiv pinakol-kobling av homokirale alfa-aminoaldehyder | |
| EP0377127A3 (de) | Verwendung von Myricetin-3-0-beta-D-glucuronid als Arzneimittel | |
| ZA88639B (en) | Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned | |
| IN172911B (xx) | ||
| CY2065B1 (en) | Use of naphthoxazines | |
| GR3003065T3 (en) | Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility | |
| ZA917001B (en) | Medicaments containing substituted 2-cyclohexene derivates and their use for the control of diseases | |
| EP0291888A3 (en) | 4-substituted 1-cyanomethylene pyrroloû4,3-e¨-benzo-azepins | |
| TW234715B (xx) | ||
| IL107142A0 (en) | Tetrahydroindazolone pharmaceutical compositions | |
| ES2103166A1 (es) | Procedimiento para la obtencion de amidinohidrazonas biciclicas. |